The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.
Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.
A biologics license application seeking the approval of a reformulation of denileukin diftitox for use as a potential therapeutic option in patients with persistent or recurrent cutaneous T-cell lymphoma has been submitted to the FDA.
The FDA has granted a fast track designation to KIN-2787 for use as a potential therapeutic option in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma.
The European Commission has approved the fixed-dose combination of relatlimab plus nivolumab for use in the frontline treatment of select patients with advanced or metastatic melanoma and a PD-L1 expression of less than 1% on tumor cells.
Adjuvant nivolumab monotherapy elicited a statistically significant and clinically meaningful improvement in recurrence-free survival compared with placebo for patients with completely resected stage IIB/C melanoma.
Compared with adjuvant pembrolizumab alone, the addition of neoadjuvant pembrolizumab significantly improved event-free survival outcomes for patients with stage III-IV melanoma with a hazard ratio of 0.58.
The investigational type II RAF inhibitor naporafenib exhibited favorable efficacy with a tolerable safety profile in combination with rineterkib, trametinib, or ribociclib in patients with previously treated, unresectable or metastatic melanoma.
A tumor-infiltrating lymphocyte therapy manufactured at various centers in the Netherlands Cancer Institute elicited a 50% reduction in the risk of progression or death vs ipilimumab in patients with stage IIIC/IV unresectable, treatment-refractory melanoma.
Immunotherapy in the form of ipilimumab plus nivolumab followed by the targeted therapy combination encorafenib plus binimetinib elicited an overall survival benefit in patients with untreated BRAF-mutated metastatic melanoma, according to findings from the phase 2 SECOMBIT trial.
A rolling biologics license application has been submitted to the FDA seeking the approval of lifileucel in patients with advanced melanoma who progressed on or after previous anti–PD-1/PD-L1 therapy, and if BRAF mutation positive, also previous BRAF or BRAF/MEK inhibitor therapy.
The addition of atezolizumab to vemurafenib and cobimetinib produced promising intracranial activity in patients with BRAF V600–mutated advanced melanoma and central nervous system metastases.
Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.
Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.
Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.
Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.
Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of the fixed-dose combination of nivolumab and relatlimab for the frontline treatment of adult and adolescents who are 12 years of age or older with advanced melanoma and a tumor cell PD-L1 expression of less than 1%.